nach oben

Erschienen in:

11.03.2020 | Review

Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment

verfasst von: M. L. Bianchi, N. J. Bishop, N. Guañabens, C. Hofmann, F. Jakob, C. Roux, M. C. Zillikens, On behalf of the Rare Bone Disease Action Group of the European Calcified Tissue Society

Erschienen in: Osteoporosis International | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

This article provides an overview of the current knowledge on hypophosphatasia—a rare genetic disease of very variable presentation and severity—with a special focus on adolescents and adults. It summarizes the available information on the many known mutations of tissue-nonspecific alkaline phosphatase (TNSALP), the epidemiology and clinical presentation of the disease in adolescents and adults, and the essential diagnostic clues. The last section reviews the therapeutic approaches, including recent reports on enzyme replacement therapy (EnzRT).

Rathbun JC (1948) Hypophosphatasia; a new developmental anomaly. Am J Dis Child 75:822–831PubMed

Hofmann C, Girschick HJ, Mentrup B, Graser S, Seefried L, Liese J, Jakob F (2013) Clinical aspects of hypophosphatasia: an update. Clinic Rev Bone Miner Metab 11:60–70

Rockman-Greenberg C (2013) Hypophosphatasia. Pediatr Endocrinol Rev 10(Suppl 2):380–388.21PubMed

Whyte MP (2016) Hypophosphatasia-aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12:233–246PubMed

Bianchi ML (2015) Hypophosphatasia: an overview of the disease and its treatment. Osteoporos Int 26:2743–2757PubMed

Sebastián-Serrano Á, de Diego-García L, Henshall DC, Engel T, Díaz-Hernández M (2018) Haploinsufficient TNAP mice display decreased extracellular ATP levels and expression of pannexin-1 channels. Front Pharmacol 9:170PubMedPubMedCentral

Strazzulla LC, Cronstein BN (2016) Regulation of bone and cartilage by adenosine signaling. Purinergic Signal 12:583–593PubMedPubMedCentral

Caswell AM, Whyte MP, Russell RG (1991) Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit Rev Clin Lab Sci 28:175–232PubMed

Cole DEC (2008) Hypophosphatasia update: recent advances in diagnosis and treatment. Clin Genet 73:232–235PubMed

10.

Mornet E (2007) Hypophosphatasia. Orphanet J Rare Dis 2:40. https://doi.org/10.1186/1750-1172-2-40 CrossRefPubMedPubMedCentral

11.

Mornet E (2008) Hypophosphatasia. Best Pract Res Clin Rheumatol 22:113–127PubMed

12.

Fraser D (1957) Hypophosphatasia. Am J Med 22:730–746PubMed

13.

Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B (2011) A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet 75:439–445PubMed

14.

Silvent J, Gasse B, Mornet E, Sire JY (2014) Molecular evolution of the tissue-nonspecific alkaline phosphatase allows prediction and validation of missense mutations responsible for hypophosphatasia. J Biol Chem 289:24168–24179PubMedPubMedCentral

15.

Griffin CA, Smith M, Henthorn PS, Harris H, Weiss MJ, Raducha M, Emanuel BS (1987) Human placental and intestinal alkaline phosphatase genes map to 2q34eq37. Am J Hum Genet 41:1025–1034PubMedPubMedCentral

16.

Mornet E, Beck C, Bloch-Zupan A, Girschick H, Le Merrer M (2011) Clinical utility gene card for: hypophosphatasia. Eur J Hum Genet 19:4–5. https://doi.org/10.1038/ejhg.2010.170 CrossRef

17.

Mornet E, Hofmann C, Bloch-Zupan A, Girschick H, Le Merrer M (2014) Clinical utility gene card for: hypophosphatasia-update 2013. Eur J Hum Genet 22(4). https://doi.org/10.1038/ejhg.2013.177

18.

Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51PubMedPubMedCentral

19.

Hu JC, Plaetke R, Mornet E, Zhang C, Sun X, Thomas HF, Simmer JP (2000) Characterization of a family with dominant hypophosphatasia. Eur J Oral Sci 108:189–194PubMed

20.

Lia-Baldini AS, Brun-Heath I, Carrion C, Simon-Bouy B, Serre JL, Nunes ME, Mornet E (2008) A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein. Hum Genet 123:429–432PubMed

21.

Lia-Baldini AS, Muller F, Taillandier A, Gibrat JF, Mouchard M, Robin B, Simon-Bouy B, Serre JL, Aylsworth AS, Bieth E, Delanote S, Freisinger P, Hu JC, Krohn HP, Nunes ME, Mornet E (2001) A molecular approach to dominance in hypophosphatasia. Hum Genet 109:99–108PubMed

22.

Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B (2014) Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet 22:1160–1164PubMedPubMedCentral

23.

Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, Coburn SP, Wagy S, Griffin DM, Ericson KL, Mumm S (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75:229–239PubMed

24.

Girschick HJ, Mornet E, Beer M, Warmuth-Metz M, Schneider P (2007) Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy. BMC Pediatr 7:3PubMedPubMedCentral

25.

Whyte MP, Wenkert D, McAlister WH, Mughal MZ, Freemont AJ, Whitehouse R, Baildam EM, Coburn SP, Ryan LM, Mumm S (2009) Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia. J Bone Miner Res 24:1493–1505PubMed

26.

Bloch-Zupan A, Vaysse F (2017) Hypophosphatasia: oral cavity and dental disorders. Arch Pediatr 24(5S2):5S80–5S84PubMed

27.

Mentrup B, Girschick H, Jakob F, Hofmann C (2017) A homozygous intronic branch-point deletion in the ALPL gene causes infantile hypophosphatasia. Bone 94:75–83PubMed

28.

Högler W, Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K, Petryk A, Rockman-Greenberg C, Seefried L, Kishnani PS (2019) Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord 20:80PubMedPubMedCentral

29.

Berkseth KE, Tebben PJ, Drake MT, Hefferan TE, Jewison DE, Wermers RA (2013) Clinical spectrum of hypophosphatasia diagnosed in adults. Bone 54:21–27PubMed

30.

Schmidt T, Mussawy H, Rolvien T, Hawellek T, Hubert J, Rüther W, Amling M, Barvencik F (2017) Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int 28:2653–2662PubMed

31.

Maman E, Briot K, Roux C (2016) Atypical femoral facture in a 51-year woman revealing a hypophosphatasia. Joint Bone Spine 83:346–348PubMed

32.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. JBMR 29(1):1–23

33.

Genest F, Seefried L (2018) Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia–not atypical at all. Osteoporos Int 29:1815–1825PubMed

34.

Sutton RA, Mumm S, Coburn SP, Ericson KL, Whyte MP (2012) “Atypical femoral fractures” during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 27:987–994PubMed

35.

Whyte MP (2009) Atypical femoral fractures, bisphosphonates, and adult hypophophatasia. J Bone Miner Res 24:1132–1134PubMed

36.

Nielson CM, Zmuda JM, Carlos AS, Wagoner WJ, Larson EA, Orwoll ES, Klein RF (2012) Rare coding variants in ALPL are associated with low serum alkaline phosphatase and low bone mineral density. J Bone Miner Res 27:93–103PubMed

37.

McKiernan FE, Berg RL, Fuehrer J (2014) Clinical and radiographic findings in adults with persistent hypophosphatasemia. J Bone Miner Res 29:1651–1660PubMed

38.

Guañabens N, Mumm S, Möller I, González-Roca E, Peris P, Demertzis JL, Whyte MP (2014) Calcific periarthritis as the only clinical manifestation of hypophosphatasia in middle-aged sisters. J Bone Miner Res 29:929–934PubMed

39.

McCarthy GM, Dunne A (2018) Calcium crystal deposition diseases-beyond gout. Nat Rev Rheumatol 14:592–602PubMed

40.

Marquez C, Toribio ML, Marcos MA, de la Hera A, Barcena A, Pezzi L, Martinez C (1989) Expression of alkaline phosphatase in murine B lymphocytes. Correlation with B cell differentiation into Ig secretion. J Immunol Baltim Md 142:3187–3192

41.

Souvannavong V, Andreau K, Adam A, Chaby R (1999) Effect of synthetic lipids on apoptosis and expression of alkaline phosphatase in B-lymphocytes: influence on lipopolysaccharide action. FEMS Immunol Med Microbiol 26:37–47PubMed

42.

Ding J, Ghali O, Lencel P, Broux O, Chauveau C, Devedjian JC, Hardouin P, Magne D (2009) TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci 84:499–504PubMed

43.

Hernandez-Chirlaque C, Gamez-Belmonte R, Ocon B, Martinez-Moya P, Wirtz S, Sanchez de Medina F, Martínez-Augustin O (2017) Tissue nonspecific alkaline phosphatase expression is needed for the full stimulation of T cells and T cell dependent colitis. J Crohns Colitis 11:857–870PubMed

44.

Lefever E, Witters P, Gielen E, Vanclooster A, Meersseman W, Morava E, Cassiman D, Laurent MR (2018) Hypophosphatasia in adults: clinical spectrum and its association with genetics and metabolic substrates. J Clin Densitom (18):30244. https://doi.org/10.1016/j.jocd.2018.12.006

45.

Whyte MP, Leelawattana R, Reinus WR, Yang C, Mumm S, Novack DV (2013) Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure. J Clin Endocrinol Metab 98:4606–4612PubMedPubMedCentral

46.

Whyte MP (2013) Enzyme defects and the skeleton. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edn. American Society for Bone and Mineral Research. Wiley-Blackwell, New York, pp 838–842

47.

Whyte MP (2017) Hypophosphatasia: an overview for 2017. Bone 102:15–25PubMed

48.

Whyte MP (2017) Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res 32:667–675PubMed

49.

Alderman JS, Wortmann (2007) Pseudogout: calcium pyrophosphate dihydrate crystal deposition disease. In: Imboden J, Hellmann D, Stone J (eds) Current rheumatology diagnosis and treatment, 2nd edn. Lange Medical Books/McGraw-Hill, New York, pp 353–357

50.

Peris P, Gonzalez-Roca R-GS, Lopez-Cobo MM, Monegal A, Guañabens N (2018) Incidence of mutations in the ALPL, GGPS1, and CYP1A1 genes in patients with atypical femoral fractures. J Bone Miner Res Plus. https://doi.org/10.1002/jbm4.10064

51.

McKiernan FE, Dong J, Berg RL, Scotty E, Mundt P, Larson L, Rai I (2017) Mutational and biochemical findings in adults with persistent hypophosphatasemia. Osteoporos Int 28:2343–2348PubMed

52.

Maman E, Borderie D, Roux C, Briot K (2016) Absence of recognition of low alkaline phosphatase level in a tertiary care hospital. Osteoporos Int 27:1251–1254PubMed

53.

Russell RG, Bisaz S, Donath A, Morgan DB, Fleisch H (1971) Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest 50:961–969PubMedPubMedCentral

54.

López-Delgado L, Riancho-Zarrabeitia L, García-Unzueta MT, Tenorio JA, García-Hoyos M, Lapunzina P, Valero C, Riancho J (2018) Abnormal bone turnover in individuals with low serum alkaline phosphatase. Osteoporos Int 29:2147–2150PubMed

55.

Mornet E (2018) Hypophosphatasia. Metabolism 82:142–155PubMed

56.

McCarthy G (2008) Calcium pyrophosphate dihydrate, hydroxyapatite, and miscellaneous crystals. In: Stone JH, Crofford LJ, White PH (eds) Primer on the rheumatic diseases, 13th edn. Springer, New York, pp 263–270

57.

Hassan S (2018) Overview of musculoskeletal ultrasound for the clinical rheumatologist. Clin Exp Rheumatol 36(suppl 114):S3–S9

58.

Naredo E, Iagnocco A, Valesini G, Uson J, Beneyto P, Crespo M (2003) Ultrasonographic study of painful shoulder. Ann Rheum Dis 62:1026–1027PubMedPubMedCentral

59.

Sumner TE, Volberg FM, Karstaedt N, Ward CF, Lorentz WB (1984) Hypophosphatasia and nephrocalcinosis demonstrated by ultrasound and CT. Clin Nephrol 22:317–319PubMed

60.

Barvencik F, Beil FT, Gebauer M, Busse B, Koehne T, Seitz S, Zustin J, Pogoda P, Schinke T, Amling M (2011) Skeletal mineralization defects in adult hypophosphatasia-a clinical and histological analysis. Osteoporos Int 22:2667–2675PubMed

61.

Fallon MD, Teitelbaum SL, Wenstein RS, Goldfischer S, Brown DM, Whyte MP (1984) Hypophosphatasia: clinicopathologic comparison of the infantile, childhood, and adult forms. Medicine (Baltimore) 14(63):12–24

62.

Ornoy A, Adomian GE, Rimoin DL (1985) Histologic and ultrastructural studies on the mineralization process in hypophosphatasia. Am J Med Genet 22:743–758PubMed

63.

Anderson HC, Hsu HH, Morris DC, Fedde KN, Whyte MP (1997) Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am J Pathol 151:1555–1561PubMedPubMedCentral

64.

Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K (2017) Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab 122:4–17PubMed

65.

Conti F, Ciullini L, Pugliese G (2017) Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab 14:230–234PubMedPubMedCentral

66.

Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS (2016) Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metab 65:1522–1530

67.

Strensiq [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2018

68.

Strensiq (summary of product characteristics). Rueil-Malmaison, France: Alexion Europe; June 8, 2017

69.

Hofmann C, Seefried L, Jakob F (2016) Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc) 52:271–285

70.

Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913PubMed

71.

Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, Mack KE, Hamilton K, Kagan K, Fujita KP, Thompson DD, Moseley S, Odrljin T, Rockman-Greenberg C (2016) Asfotase alfa therapy for children with hypophosphatasia. JCI Insight 1:e85971PubMedPubMedCentral

72.

Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C (2016) Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab 101:334–342PubMed

73.

Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP (2019) Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone 121:149–162PubMed

74.

Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH (2019) Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 7:93–105PubMed

75.

Bowden SA, Adler BH (2018) Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia. Osteoporos Int 29:2155–2156PubMed

76.

Skrzypczyk P, Pańczyk-Tomaszewska M (2017) Methods to evaluate arterial structure and function in children-state-of-the art knowledge. Adv Med Sci 62:280–294PubMed

77.

Flore R, Zocco MA, Ainora ME, Fonnesu C, Nesci A, Gasbarrini A, Ponziani FR (2018) A novel ultrasound-based vascular calcification score (CALCS) to detect subclinical atherosclerosis. Eur Rev Med Pharmacol Sci 22:736–742PubMed

78.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group (2019) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz486

79.

Girschick HJ, Seyberth HW, Huppertz HI (1999) Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs. Bone 25:603–607PubMed

80.

Girschick HJ, Schneider P, Haubitz I, Hiort O, Collmann H, Beer M, Shin YS, Seyberth HW (2006) Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia. Orphanet J Rare Dis 1:24PubMedPubMedCentral

81.

Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ (2009) How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int 29:229–238PubMed

82.

Collmann H, Mornet E, Gattenlohner S, Beck C, Girschick H (2009) Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst 25:217–223PubMed

83.

Otero JE, Gottesman GS, McAlister WH, Mumm S, Madson KL, Kiffer-Moreira T, Sheen C, Millan JL, Ericson KL, Whyte MP (2013) Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. J Bone Miner Res 28:419–430PubMed

84.

Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N (2018) Atypical femur fractures-review of epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocr Rev. https://doi.org/10.1210/er.2018-00001

85.

Doshi KB, Hamrahian AH, Licata AA (2009) Teriparatide treatment in adult hypophosphatasia in a patient exposed to bisphosphonate: a case report. Clin Cases Miner Bone Metab 6:266–269PubMed

86.

Gagnon C, Sims NA, Mumm S, McAuley SA, Jung C, Poulton IJ, Ng KW, Ebeling PR (2010) Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab 95:1007–1012PubMed

87.

Laroche M (2012) Failure of teriparatide in treatment of bone complications of adult hypophosphatasia. Calcif Tissue Int 90:250. https://doi.org/10.1007/s00223-011-9562-5 CrossRefPubMed

88.

Schalin-Jantti C, Mornet E, Lamminen A, Valimaki MJ (2010) Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia. J Clin Endocrinol Metab 95:5174–5179PubMed

89.

Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, Huang Y, Chivers S, Valentin MA, Borah B, Roubenoff R, Junker U, Jakob F (2017) Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest 127:2148–2158PubMedPubMedCentral

90.

Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res 32:1027–1033PubMed

Titel: Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment
verfasst von: M. L. Bianchi
N. J. Bishop
N. Guañabens
C. Hofmann
F. Jakob
C. Roux
M. C. Zillikens
On behalf of the Rare Bone Disease Action Group of the European Calcified Tissue Society
Publikationsdatum: 11.03.2020
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 8/2020
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05345-9

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment

Abstract

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study

Existing severe osteoporotic vertebral fractures in elderly Chinese males were only weakly associated with higher further vertebral fracture risk at year-4 follow-up

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis

Correspondence to “Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?”

Real-world effectiveness of osteoporosis treatment in the oldest old

The risk of new fragility fractures in patients with chronic kidney disease and hip fracture—a population-based cohort study in the UK

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie